Total Payments
$11,939
2024 Payments
$1,985
Companies
59
Transactions
950
Medicare Patients
7,878
Medicare Billing
$866,341
Payment Breakdown by Category
Food & Beverage$11,839 (99.2%)
Education$99.89 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,839 | 933 | 99.2% |
| Education | $99.89 | 17 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,381 | 129 | $0 (2024) |
| Amgen Inc. | $1,196 | 101 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,164 | 48 | $0 (2024) |
| PFIZER INC. | $1,150 | 125 | $0 (2024) |
| Novo Nordisk Inc | $1,012 | 93 | $0 (2024) |
| GlaxoSmithKline, LLC. | $783.96 | 56 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $667.48 | 41 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $650.64 | 61 | $0 (2024) |
| Merck Sharp & Dohme LLC | $494.16 | 41 | $0 (2024) |
| Allergan, Inc. | $287.71 | 40 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,985 | 124 | ABBVIE INC. ($392.89) |
| 2023 | $2,313 | 155 | ABBVIE INC. ($477.97) |
| 2022 | $1,457 | 115 | ABBVIE INC. ($189.66) |
| 2021 | $770.63 | 59 | AbbVie Inc. ($218.52) |
| 2020 | $466.51 | 41 | Allergan, Inc. ($122.42) |
| 2019 | $1,607 | 144 | AstraZeneca Pharmaceuticals LP ($311.79) |
| 2018 | $1,568 | 140 | Amgen Inc. ($300.77) |
| 2017 | $1,773 | 172 | Boehringer Ingelheim Pharmaceuticals, Inc. ($245.72) |
All Payment Transactions
950 individual payment records from CMS Open Payments — Page 1 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: PAIN | ||||||
| 12/16/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $12.15 | General |
| Category: NEUROSCIENCE | ||||||
| 12/13/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/06/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $23.12 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: PSYCHIATRY | ||||||
| 12/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: DIABETES | ||||||
| 11/25/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: PSYCHIATRY | ||||||
| 11/22/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: Diabetes | ||||||
| 11/15/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: RESPIRATORY | ||||||
| 11/15/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $13.23 | General |
| Category: Obesity | ||||||
| 11/12/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $23.10 | General |
| Category: PSYCHIATRY | ||||||
| 11/12/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $16.14 | General |
| Category: PSYCHIATRY | ||||||
| 11/11/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.47 | General |
| Category: NEUROSCIENCE | ||||||
| 11/06/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $27.79 | General |
| Category: PSYCHIATRY | ||||||
| 11/05/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $9.96 | General |
| Category: NEUROSCIENCE | ||||||
| 11/04/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.21 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $8.39 | General |
| Category: NEUROSCIENCE | ||||||
| 10/28/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: PSYCHIATRY | ||||||
| 10/25/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $15.87 | General |
| Category: PSYCHIATRY | ||||||
| 10/23/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $13.29 | General |
| Category: PAIN | ||||||
| 10/22/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $14.18 | General |
| 10/14/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $0.41 | General |
| Category: PSYCHIATRY | ||||||
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $15.44 | General |
| Category: Cardiovascular | ||||||
| 10/10/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $5.94 | General |
| Category: NEUROSCIENCE | ||||||
| 10/08/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: VACCINES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 2,233 | 3,950 | $778,679 | $252,092 |
| 2022 | 21 | 1,957 | 3,502 | $688,030 | $217,266 |
| 2021 | 21 | 1,944 | 3,686 | $691,371 | $223,897 |
| 2020 | 20 | 1,744 | 3,031 | $494,352 | $173,086 |
Total Patients
7,878
Total Services
14,169
Medicare Billing
$866,341
Procedure Codes
85
All Medicare Procedures & Services
85 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 400 | 1,595 | $336,545 | $91,958 | 27.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 279 | 279 | $63,612 | $33,511 | 52.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 260 | 423 | $71,910 | $22,953 | 31.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 190 | 297 | $73,656 | $22,386 | 30.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 161 | 165 | $77,220 | $20,654 | 26.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 139 | 145 | $38,135 | $12,110 | 31.8% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 42 | 42 | $27,300 | $11,862 | 43.5% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 134 | 136 | $18,360 | $10,282 | 56.0% |
| 91320 | Sarscv2 vac 30mcg trs-suc im | Office | 2023 | 39 | 39 | $7,605 | $5,011 | 65.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 135 | 137 | $5,480 | $3,922 | 71.6% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 16 | 16 | $4,144 | $2,463 | 59.4% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 47 | 56 | $15,535 | $2,450 | 15.8% |
| 87637 | Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | Office | 2023 | 16 | 16 | $6,320 | $2,236 | 35.4% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 14 | 14 | $5,236 | $2,151 | 41.1% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 27 | 28 | $5,236 | $2,006 | 38.3% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 39 | 39 | $1,911 | $1,489 | 77.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 78 | 160 | $7,360 | $1,341 | 18.2% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 42 | 42 | $1,638 | $1,202 | 73.4% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 89 | 130 | $4,030 | $967.03 | 24.0% |
| 0124A | Adm sarscv2 bvl 30mcg/.3ml a | Office | 2023 | 23 | 24 | $1,176 | $916.08 | 77.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 14 | 15 | $1,230 | $126.84 | 10.3% |
| 81003 | Automated urinalysis test | Office | 2023 | 21 | 24 | $432.00 | $52.80 | 12.2% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 28 | 128 | $4,608 | $41.69 | 0.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 314 | 1,337 | $282,107 | $70,031 | 24.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 249 | 418 | $103,664 | $32,239 | 31.1% |
About Dr. Craig Haseman, MD
Dr. Craig Haseman, MD is a Family Medicine healthcare provider based in Evansville, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265449649.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Craig Haseman, MD has received a total of $11,939 in payments from pharmaceutical and medical device companies, with $1,985 received in 2024. These payments were reported across 950 transactions from 59 companies. The most common payment nature is "Food and Beverage" ($11,839).
As a Medicare-enrolled provider, Haseman has provided services to 7,878 Medicare beneficiaries, totaling 14,169 services with total Medicare billing of $866,341. Data is available for 4 years (2020–2023), covering 85 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Evansville, IN
- Active Since 08/01/2006
- Last Updated 12/16/2014
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1265449649
Products in Payments
- REXULTI (Drug) $741.92
- FARXIGA (Drug) $669.45
- VRAYLAR (Drug) $646.02
- UBRELVY (Drug) $564.00
- Prolia (Biological) $403.54
- EVENITY (Biological) $361.04
- CHANTIX (Drug) $356.88
- TRELEGY ELLIPTA (Drug) $344.49
- JARDIANCE (Drug) $297.58
- Ozempic (Drug) $287.79
- Rybelsus (Drug) $266.15
- SHINGRIX (Biological) $261.07
- JANUVIA (Drug) $256.53
- NURTEC ODT (Drug) $253.53
- QULIPTA (Drug) $221.59
- Auvelity (Drug) $174.93
- CAPLYTA (Drug) $166.72
- Saxenda (Drug) $156.71
- ELIQUIS (Drug) $154.02
- Aimovig (Biological) $146.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Evansville
David Schultz, M.d, M.D
Family Medicine — Payments: $756,324
Family Medicine $756,324
J Sartore, Md, MD
Family Medicine — Payments: $425,777
Family Medicine $425,777
Dr. Anthony Inzerello, M.d, M.D
Family Medicine — Payments: $315,157
Family Medicine $315,157
Carol Goodman, Md, MD
Family Medicine — Payments: $125,655
Family Medicine $125,655
Randall Oliver, M.d, M.D
Family Medicine — Payments: $75,540
Family Medicine $75,540
David Brougher, M.d, M.D
Family Medicine — Payments: $62,934
Family Medicine $62,934